802 related articles for article (PubMed ID: 23918952)
1. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Li J; Qin S; Xu J; Guo W; Xiong J; Bai Y; Sun G; Yang Y; Wang L; Xu N; Cheng Y; Wang Z; Zheng L; Tao M; Zhu X; Ji D; Liu X; Yu H
J Clin Oncol; 2013 Sep; 31(26):3219-25. PubMed ID: 23918952
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
3. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy.
Ruan H; Dong J; Zhou X; Xiong J; Wang H; Zhong X; Cao X
Oncotarget; 2017 Nov; 8(61):104552-104559. PubMed ID: 29262660
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
7. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Qin S; Li Q; Gu S; Chen X; Lin L; Wang Z; Xu A; Chen X; Zhou C; Ren Z; Yang L; Xu L; Bai Y; Chen L; Li J; Pan H; Cao B; Fang W; Wu W; Wang G; Cheng Y; Yu Z; Zhu X; Jiang D; Lu Y; Wang H; Xu J; Bai L; Liu Y; Lin H; Wu C; Zhang Y; Yan P; Jin C; Zou J
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):559-568. PubMed ID: 33971141
[TBL] [Abstract][Full Text] [Related]
8. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
10. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
17. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Koo DH; Ryu MH; Ryoo BY; Seo J; Lee MY; Chang HM; Lee JL; Lee SS; Kim TW; Kang YK
Gastric Cancer; 2015 Apr; 18(2):346-53. PubMed ID: 24832201
[TBL] [Abstract][Full Text] [Related]
18. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
19. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
20. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
